Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Sintilimab in Triple Negative Breast Cancer: NCT05843292 Clinical Landscape Report 2026
16 October 2026
NCT05843292 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Elemene in Glioblastoma, IDH-Wildtype: NCT05842746 Clinical Landscape Report 2026
16 October 2026
NCT05842746 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in PD-L1 positive Triple Negative Breast Cancer: NCT05852691 Clinical Landscape Report 2026
16 October 2026
NCT05852691 clinical landscape for PD-L1 positive Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
AI-061 in Primary peritoneal carcinoma: NCT05858736 Clinical Landscape Report 2026
16 October 2026
NCT05858736 clinical landscape for Primary peritoneal carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fulvestrant in Endometrial Carcinoma: NCT05867251 Clinical Landscape Report 2026
16 October 2026
NCT05867251 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trilaciclib Dihydrochloride in Triple Negative Breast Cancer: NCT05862610 Clinical Landscape Report 2026
16 October 2026
NCT05862610 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Erdafitinib in Recurrent Glioma: NCT05859334 Clinical Landscape Report 2026
16 October 2026
NCT05859334 clinical landscape for Recurrent Glioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Triple Negative Breast Cancer: NCT05862064 Clinical Landscape Report 2026
16 October 2026
NCT05862064 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zirconium (89Zr) girentuximabum senvedoxamum in Renal Cell Carcinoma: NCT05861778 Clinical Landscape Report 2026
16 October 2026
NCT05861778 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Doxorubicin Hydrochloride liposomal in Gliosarcoma: NCT05864534 Clinical Landscape Report 2026
16 October 2026
NCT05864534 clinical landscape for Gliosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RC-198 in Locally Advanced Malignant Solid Neoplasm: NCT05867303 Clinical Landscape Report 2026
16 October 2026
NCT05867303 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
SNC-109 in Recurrent Glioblastoma: NCT05868083 Clinical Landscape Report 2026
16 October 2026
NCT05868083 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.